| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Pseudoginsenoside RT1 does not have a single defined pharmacological target. Its primary reported activities are physiological, including causing a decrease in blood pressure, an increase in heart rate, and an increase in spontaneous contractility of the uterus. It also exhibits acute ichthyotoxic activity. These effects suggest it interacts with multiple systems, possibly involving cardiovascular and smooth muscle targets.
|
|---|---|
| ln Vitro |
In vitro, Pseudoginsenoside RT1 has been studied for its ichthyotoxic activity. This activity is likely due to its effects on cellular membranes or ion channels in fish. Its effects on smooth muscle contraction have also been characterized, suggesting it can modulate uterine contractility.
|
| ln Vivo |
In vivo, Pseudoginsenoside RT1 has been shown to cause a decrease in blood pressure, an increase in heart rate, and an increase in spontaneous contractility of the uterus. These effects indicate it has potent cardiovascular and smooth muscle activity. However, detailed in vivo efficacy data are limited. The compound is primarily used as a research tool.
|
| Enzyme Assay |
For in vitro assays, the activity of Pseudoginsenoside RT1 can be assessed. Its ichthyotoxic activity can be evaluated using a fish bioassay. Its effects on smooth muscle contraction can be studied using isolated tissue baths, where uterine or vascular smooth muscle strips are treated with the compound, and isometric tension is measured.
|
| Cell Assay |
For in vitro cell-based assays, the effects of Pseudoginsenoside RT1 can be studied on smooth muscle cell lines or cardiomyocytes. Cells are treated with the compound, and changes in intracellular calcium levels or contractility are measured. Its effects on cell viability and cytotoxicity can also be assessed.
|
| Animal Protocol |
For in vivo animal studies, Pseudoginsenoside RT1 is typically administered intravenously or intraperitoneally. Its effects on blood pressure and heart rate can be measured using telemetry or a tail-cuff method in rodents. Its uterotonic effects can be studied in pregnant or non-pregnant animal models.
|
| ADME/Pharmacokinetics |
Pseudoginsenoside RT1 has a molecular weight of 927.1. As a saponin, it is expected to have poor oral bioavailability. Detailed pharmacokinetic parameters are not publicly available.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Pseudoginsenoside RT1 are limited. As a natural saponin, it may have hemolytic activity at high concentrations. The compound is used for research purposes only and is not intended for human use. Standard laboratory safety precautions should be observed.
|
| References | |
| Additional Infomation |
RT1, a pseudoginsenoside, is a triterpenoid saponin that acts as a metabolite. It has been reported that RT1 exists in ginseng (Panax japonicus) and caroxylon imbricatum, and relevant data are available for reference.
Pseudoginsenoside RT1 is a research compound with no clinical trial or regulatory approval status. It is a natural product isolated from various plant sources. It is used as a research tool to study cardiovascular and smooth muscle physiology. It is commercially available from chemical suppliers for research purposes only. |
| Molecular Formula |
C47H74O18
|
|---|---|
| Molecular Weight |
927.0797
|
| Exact Mass |
926.488
|
| CAS # |
98474-74-9
|
| PubChem CID |
21633069
|
| Appearance |
White to off-white solid powder
|
| Density |
1.42±0.1 g/cm3
|
| Boiling Point |
987.3±65.0 °C(Predicted)
|
| Melting Point |
235-238 °C
|
| LogP |
0.871
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
65
|
| Complexity |
1830
|
| Defined Atom Stereocenter Count |
22
|
| SMILES |
C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)(C)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O
|
| InChi Key |
YTPBUIWNJRGZFW-HONMPOSFSA-N
|
| InChi Code |
InChI=1S/C47H74O18/c1-42(2)14-16-47(41(59)65-39-34(56)30(52)29(51)24(19-48)61-39)17-15-45(6)21(22(47)18-42)8-9-26-44(5)12-11-27(43(3,4)25(44)10-13-46(26,45)7)62-40-36(32(54)31(53)35(63-40)37(57)58)64-38-33(55)28(50)23(49)20-60-38/h8,22-36,38-40,48-56H,9-20H2,1-7H3,(H,57,58)/t22-,23+,24+,25-,26+,27-,28-,29+,30-,31-,32-,33+,34+,35-,36+,38-,39-,40+,44-,45+,46+,47-/m0/s1
|
| Chemical Name |
(2S,3S,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,12aS,14aR,14bR)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4-dihydroxy-5-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~107.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.55 mg/mL (4.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 45.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.70 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0787 mL | 5.3933 mL | 10.7866 mL | |
| 5 mM | 0.2157 mL | 1.0787 mL | 2.1573 mL | |
| 10 mM | 0.1079 mL | 0.5393 mL | 1.0787 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
